Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer — XPID

Stage IV Gastric Cancer With Metastasis Clinical Trial

Official title:
A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding

Status Completed

Clinical Trial Summary

A maximum of 8 cycles of chemotherapy will be administered. Depending on patients' tolerability, 8 cycles of chemotherapy will be given to the patients.

Clinical Trial Description

Single-center, open-label, prospective, single-arm, phase I-II study

About 37 patients (Phase I 18, Phase II 31 (including 12 patients from Phase I) ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Stage IV Gastric Cancer With Metastasis
Stomach Neoplasms

Clinical Trial Details

NCT number	NCT01525771
Study type	Interventional
Source	Asan Medical Center
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	February 2011
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01964027` - The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer	Phase 2
Recruiting	`NCT03604614` - Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis	Phase 2
Not yet recruiting	`NCT05441254` - Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study	Phase 2
Active, not recruiting	`NCT03237507` - Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer	N/A
Completed	`NCT01503983` - Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive	Phase 2